Metered-dose intestinal oxygen delivery therapeutic - LPOXY Therapeutics
Alternative Names: LP-102 - LPOXY Therapeutics; Sidiprev - LPOXY TherapeuticsLatest Information Update: 31 Mar 2025
At a glance
- Originator LPOXY Therapeutics
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Colitis; Crohn's disease; Ulcerative colitis
Most Recent Events
- 05 Feb 2025 Sidiprev - LPOXY Therapeutics is available for licensing as of 05 Feb 2025. https://www.lpoxy.com/company
- 05 Feb 2025 Phase-I clinical trials in Crohn's disease (PO) prior to January 2025 (LPOXY Therapeutics Pipeline, January 2025)
- 05 Feb 2025 Phase-I clinical trials in Ulcerative colitis (PO) prior to January 2025 (LPOXY Therapeutics Pipeline, January 2025)